Vertaling van "first pa-european study " (Frans → Nederlands) :

Lepine JP, Gastpar, Mendlecicz J, Tylee A. Depression in the community: the first pa-European study DEPRES (Depression Research in European Society).
Lepine JP, Gastpar, Mendlecicz J, Tylee A. Depression in the community : the first pa-European study DEPRES (Depression Research in European Society).

Tableau 5. Principales conférences organisées sur le thème de la santé des médecins Année Titre de la Conférence Organisateur 1996 First European research conference on physicians ‘health NMA 2001 First European Meeting PAIMM PAIMM 2004 International Conference on Physician Health: Creating a healthy CMA culture in medicine 2008 Doctor’s health matters : finding the balance AMA CMA BMA
Tabel 5. Belangrijkste conferenties over de gezondheid van artsen Jaar Titel van de Conferentie Organisator 1996 First European research conference on physicians ‘health NMA 2001 First European Meeting PAIMM PAIMM 2004 International Conference on Physician Health: Creating a healthy culture CMA in medicine 2008 Doctor’s health matters: finding the balance AMA CMA BMA

Coenen S, Costers M, De Corte S, De Sutter A, Goossens H. The first European Antibiotic Awareness Day after a decade of improving outpatient antibiotic use in Belgium.
Coenen S, Costers M, De Corte S, De Sutter A, Goossens H. The first European Antibiotic Awareness Day after a decade of improving outpatient antibiotic use in Belgium.

L’European Study on Epidemiology of Mental Disorders (ESEMeD) est une étude sur les troubles mentaux au niveau de la population dans 6 pays européens (Belgique, France, Allemagne, Italie, Pays-Bas et Espagne).
The European Study on Epidemiology of Mental Disorders (ESEMeD) is a study focussing on the mental disorders in the population of six European countries (Belgium, France, Germany, Italy, the Netherlands and Spain).

3.1.2. L’European Study on Epidemiology of Mental Disorders (ESEMeD)
3.1.2 European Study on Epidemiology of Mental Disorders (ESEMeD)

Source: Bruffaerts et al. La prévalence des troubles mentaux dans la population belge; Résultats de l’European Study on Epidemiology of Mental Disorders (ESEMeD).
Source: Bruffaerts et al. La prévalence des troubles mentaux dans la population belge. Results of the European Study on Epidemiology of Mental Disorders (ESEMeD), Louvain Med. 2003; 122:321-334.

Résultats de l’european study on epidemiology of mental disorders (ESMeD) . Louvain Med. 122:321-334, 2003.
Resultaten van de European Study on Epidemiology of Mental Disorders (ESMeD), Tijdschr.voor Geneeskunde 2004; 60, nr..

o European Society of Clinical Microbiology and Infectious Diseases/Study Group on Antibiotic Policies.
ii European Society of Clinical Microbiology and Infectious Diseases/Study Group on Antibiotic Policies.

Résultats de l’European Study on Epidemiology of Mental Disorders (ESEMeD) in Rev Med Liège 2004; 59: 3: 136-144.
Résultats de l’European Study on Epidemiology of Mental Disorders (ESEMeD) in Rev Med Liège 2004 ; 59 : 3 : 136-144.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.